Thema: News: Dacarbazine and fotemustine in newly diagnosed GBM
News: Dacarbazine and fotemustine in newly diagnosed GBM
Katja[a]
28.03.2003 22:31:16
Br J Cancer 2003 Feb 24;88(4):496-501 (Abstract)
Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
Fazeny-Dorner B, Veitl M, Wenzel C, Rossler K, Ungersbock K, Dieckmann K, Piribauer M, Hainfellner J, Marosi C
A total of 55 patients with histologically proven glioblastoma multiforme (total gross resection: n=24, subtotal resection: n=20, stereotactic biopsy: n=11) were treated with the combination of dacarbazine (D) (200 mg m(-2)) and fotemustine (F) (100 mg m(-2)) and concomitant radiotherapy (2 Gy day(-1), 5 days per week using limited fields up to 60 Gy) to assess efficacy and toxicity of this regimen.
Survival (median survival, 12-, 18- and 24-month survival rates) and time to progression (median time to progression (TTP), 6-month progression-free survival) were analysed by Kaplan-Meier´s method.
A total of 268 (range 1-8, median: 5) cycles were administered.
Median survival is 14.5+ (range: 0.5-40+) months, and the 12-, 18- and 24-month survival rates are 58, 29 and 23%, respectively.
Median TTP from the start of D/F therapy is 9.5+ (range: 0.5-33+) months.
The 6-month progression-free survival is 54%.
Partial remissions were observed in 3.6%.
Main toxicity was thrombocytopenia.
Five patients were excluded from further D/F application, four patients because of prolonged thrombocytopenia NCI-CTC grades 3 and 4 and one patient because of whole body erythrodermia.
One patient died because of septic fever during thrombocytopenia and leukopenia NCI-CTC grade 4 after the first cycle.
No other toxicities of NCI-CTC grade 3 or 4 occurred.
The treatment is feasible in a complete outpatient setting and the results of the D/F regimen justify further investigations with these compounds.
Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
Fazeny-Dorner B, Veitl M, Wenzel C, Rossler K, Ungersbock K, Dieckmann K, Piribauer M, Hainfellner J, Marosi C
A total of 55 patients with histologically proven glioblastoma multiforme (total gross resection: n=24, subtotal resection: n=20, stereotactic biopsy: n=11) were treated with the combination of dacarbazine (D) (200 mg m(-2)) and fotemustine (F) (100 mg m(-2)) and concomitant radiotherapy (2 Gy day(-1), 5 days per week using limited fields up to 60 Gy) to assess efficacy and toxicity of this regimen.
Survival (median survival, 12-, 18- and 24-month survival rates) and time to progression (median time to progression (TTP), 6-month progression-free survival) were analysed by Kaplan-Meier´s method.
A total of 268 (range 1-8, median: 5) cycles were administered.
Median survival is 14.5+ (range: 0.5-40+) months, and the 12-, 18- and 24-month survival rates are 58, 29 and 23%, respectively.
Median TTP from the start of D/F therapy is 9.5+ (range: 0.5-33+) months.
The 6-month progression-free survival is 54%.
Partial remissions were observed in 3.6%.
Main toxicity was thrombocytopenia.
Five patients were excluded from further D/F application, four patients because of prolonged thrombocytopenia NCI-CTC grades 3 and 4 and one patient because of whole body erythrodermia.
One patient died because of septic fever during thrombocytopenia and leukopenia NCI-CTC grade 4 after the first cycle.
No other toxicities of NCI-CTC grade 3 or 4 occurred.
The treatment is feasible in a complete outpatient setting and the results of the D/F regimen justify further investigations with these compounds.
Katja[a]
